​

Y-mAbs Therapeutics (YMAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

YMAB Stock Forecast

Y-mAbs Therapeutics (YMAB) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $15.50, with a high of $24.00 and a low of $7.00. This represents a 230.49% increase from the last price of $4.69.

- $5 $10 $15 $20 $25 High: $24 Avg: $15.5 Low: $7 Last Closed Price: $4.69

YMAB Stock Rating

Y-mAbs Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (64.29%), 3 Hold (21.43%), 2 Sell (14.29%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 2 3 9 Strong Sell Sell Hold Buy Strong Buy

YMAB Price Target Upside V Benchmarks

TypeNameUpside
StockY-mAbs Therapeutics230.49%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-14
Avg Price Target-$7.00$18.50
Last Closing Price$4.69$4.69$4.69
Upside/Downside-49.25%294.46%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 251711-10
Mar, 252711-11
Feb, 252711-11
Jan, 252711-11
Dec, 242711-11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2025Morgan Stanley$7.00$4.8544.33%49.25%
Nov 11, 2024Etzer DaroutBMO Capital$24.00$15.0659.36%411.73%
Jun 28, 2024Nicole GerminoTruist Financial$21.00$12.3370.32%347.76%
May 10, 2024Robert BurnsH.C. Wainwright$22.00$12.8770.94%369.08%
Apr 05, 2024Etzer DaroutBMO Capital$26.00$14.5678.57%454.37%
May 10, 2023YMAB)to OutperformWedbush$13.00$9.9031.31%177.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2024Cantor FitzgeraldUnderperformUnderperformhold
Aug 16, 2024Cantor FitzgeraldOverweightinitialise
Aug 13, 2024Morgan StanleyBuyBuyhold
May 10, 2024H.C. WainwrightBuyBuyhold
Apr 05, 2024BMO CapitalOutperformOutperformhold
May 10, 2023WedbushOutperformupgrade
Jan 05, 2023Cowen & Co.Market Performdowngrade
Oct 31, 2022GuggenheimBuyBuyhold
Oct 31, 2022GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.95$-1.30$-2.20$-0.49$-0.67----
Avg Forecast$-2.99$-1.08$-2.70$-0.67$-0.63$-0.58$-0.62$-0.76$-1.02
High Forecast$-2.77$-1.00$-2.46$-0.63$-0.55$-0.25$-0.38$-0.46$-0.90
Low Forecast$-3.19$-1.15$-3.01$-0.71$-0.73$-1.01$-0.82$-1.09$-1.17
Surprise %-1.34%20.37%-18.52%-26.87%6.35%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$20.75M$34.90M$65.27M$84.82M$87.69M----
Avg Forecast$15.48M$35.88M$54.93M$82.21M$88.30M$104.55M$112.91M$124.05M$129.93M
High Forecast$16.28M$37.72M$59.83M$83.12M$89.45M$117.21M$115.05M$125.92M$144.84M
Low Forecast$14.60M$33.83M$51.28M$80.98M$87.15M$96.00M$110.77M$122.18M$118.63M
Surprise %34.00%-2.73%18.82%3.18%-0.70%----

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-118.34M$-56.34M$-96.33M$-21.43M$-29.67M----
Avg Forecast$-99.61M$-24.40M$-122.09M$-21.43M$-27.96M$-29.35M$-26.25M$-33.81M$-44.34M
High Forecast$-79.69M$3.91M$-97.67M$-17.14M$-23.90M$-10.79M$-16.76M$-19.97M$-39.33M
Low Forecast$-119.54M$-52.70M$-146.50M$-25.71M$-32.01M$-44.10M$-35.74M$-47.65M$-50.96M
Surprise %18.80%130.96%-21.10%-6.11%----

YMAB Forecast FAQ

Is Y-mAbs Therapeutics stock a buy?

Y-mAbs Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 3 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Y-mAbs Therapeutics is a favorable investment for most analysts.

What is Y-mAbs Therapeutics's price target?

Y-mAbs Therapeutics's price target, set by 14 Wall Street analysts, averages $15.5 over the next 12 months. The price target range spans from $7 at the low end to $24 at the high end, suggesting a potential 230.49% change from the previous closing price of $4.69.

How does Y-mAbs Therapeutics stock forecast compare to its benchmarks?

Y-mAbs Therapeutics's stock forecast shows a 230.49% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Y-mAbs Therapeutics over the past three months?

  • April 2025: 10.00% Strong Buy, 70.00% Buy, 10.00% Hold, 10.00% Sell, 0% Strong Sell.
  • March 2025: 18.18% Strong Buy, 63.64% Buy, 9.09% Hold, 9.09% Sell, 0% Strong Sell.
  • February 2025: 18.18% Strong Buy, 63.64% Buy, 9.09% Hold, 9.09% Sell, 0% Strong Sell.

What is Y-mAbs Therapeutics’s EPS forecast?

Y-mAbs Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.58, marking a -13.43% decrease from the reported $-0.67 in 2024. Estimates for the following years are $-0.62 in 2026, $-0.76 in 2027, and $-1.02 in 2028.

What is Y-mAbs Therapeutics’s revenue forecast?

Y-mAbs Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $104.55M, reflecting a 19.23% increase from the reported $87.68M in 2024. The forecast for 2026 is $112.91M, followed by $124.05M for 2027, and $129.93M for 2028.

What is Y-mAbs Therapeutics’s net income forecast?

Y-mAbs Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-29.346M, representing a -1.08% decrease from the reported $-29.666M in 2024. Projections indicate $-26.252M in 2026, $-33.81M in 2027, and $-44.344M in 2028.